PDF Cover

Samarium-153 EDTMP Market

The market for Samarium-153 EDTMP was estimated at $172 million in 2025; it is anticipated to increase to $234 million by 2030, with projections indicating growth to around $318 million by 2035.

Report ID:DS1802023
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Samarium-153 EDTMP
Share
Connect
Report Price: $4,200
Report Summary
Market Data
Methodology
Table of Contents

Global Samarium-153 EDTMP Market Outlook

Revenue, 2025

$172M

Forecast, 2035

$317M

CAGR, 2026 - 2035

6.3%

The Samarium-153 EDTMP industry revenue is expected to be around $172.4 million in 2026 and expected to showcase growth with 6.3% CAGR between 2026 and 2035. The Samarium-153 EDTMP market maintains its position as a vital segment of worldwide radiopharmaceuticals because of increasing osteoblastic bone metastases cases and aging cancer patients and the requirement for precise radionuclide therapy that provides fast pain relief with controlled side effects. The end-user adoption of Samarium-153 EDTMP reaches 95.9% through Hospitals and Specialty Clinics because the therapy has become deeply integrated into specialist nuclear medicine services and palliative care oncology workflows. The osteoblastic Bone Metastase Disease indication produces $158.79 million in Samarium-153 EDTMP industry revenue during 2025 because doctors show strong confidence in the treatment and follow established guidelines while receiving adequate reimbursement support. The therapy maintains its importance because healthcare organizations focus on delivering high-quality life outcomes while searching for affordable solutions to treat complex bone metastases cases. The samarium-153 isotope in ethylenediaminetetramethylene phosphonate chelation allows the radiopharmaceutical to target osteoblastic active areas for delivering targeted radiation to painful bone lesions. The therapy achieves its purpose through its ability to bind strongly to bone tissue and its stable elimination pattern and its single-dose administration method which makes it suitable for treating osteoblastic bone metastases in prostate cancer and breast cancer patients.

The main uses of Samarium-153 EDTMP also known as Quadramet, include treating unmanageable bone pain from metastatic disease and supporting cancer treatment plans and caring for patients with advanced cancer who cannot receive external beam radiation. The growing use of multimodal bone metastases treatment protocols in Hospitals and Specialty Clinics together with theranostic method adoption and improved radiopharmaceutical distribution networks drive Samarium-153 EDTMP market growth in both established and developing healthcare systems.

Samarium-153 EDTMP market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035
Samarium-153 EDTMP Market Outlook

Market Key Insights

  • The Samarium-153 Edtmp market is projected to grow from $172.4 million in 2025 to $318 million in 2035. This represents a CAGR of 6.3%, reflecting rising demand across Bone Pain Palliation, Osteosarcoma Treatment, and Radiotherapy.

  • This is a highly consolidated market with 2 key players, where Lantheus Medical Imaging Inc. holds the dominant share.

  • U.S. and Germany are the top markets within the Samarium 153 Edtmp market and are expected to observe the growth CAGR of 4.1% to 6.0% between 2025 and 2030.

  • Emerging markets including India, South Korea and Brazil are expected to observe highest growth with CAGR ranging between 7.2% to 8.7%.

  • End-User Companies within Hospitals are adopting transition like From Niche Palliative to Strategic Radiopharmaceutical Asset; and this trend is expected to give an additional push of $8 million to Samarium 153 Edtmp industry b/w 2025 and 2030.

    .

  • The Samarium 153 Edtmp market is set to add $145 million between 2025 and 2035, with manufacturer targeting Specialty Clinics & Others Application projected to gain a larger market share.

  • With

    innovative applications in oncology, and

    Technological Advancements, Samarium 153 Edtmp market to expand 84% between 2025 and 2035.

samarium 153 edtmp market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Samarium-153 EDTMP - Country Share Analysis

Opportunities in the Samarium-153 EDTMP

The medical field of nuclear medicine oncology experiences transformation because Samarium-153 EDTMP now treats osteoblastic bone metastases. The market for osteoblastic bone metastases treatments will also experience increasing demand because Samarium-153 EDTMP stands ready to meet this growing need. The targeted radionuclide therapy provides better safety outcomes and faster pain relief for oncology centers which makes it more valuable than standard pain medications and external beam radiation therapy. The global radiopharmaceutical market will experience its most significant growth from osteoblastic bone metastases products and other bone-targeting agents.

Growth Opportunities in North America and Asia-Pacific

The adoption of Samarium-153 EDTMP in North America occurs because of two main factors: the widespread occurrence of metastatic bone disease and the existing nuclear medicine facilities and doctors' experience with bone metastases treatment using radiopharmaceuticals. The End-User segment of large tertiary Hospitals leads the adoption of Samarium-153 EDTMP because they have the most influence while Specialty Clinics show faster growth in outpatient oncology palliative care services. The main business opportunities for Samarium-153 EDTMP involve its integration into hospital-wide oncology treatment protocols for bone metastasis patients and the development of joint clinical guidelines with cancer centers to establish market leadership against other radiopharmaceuticals and non-isotopic pain management options. The market competition exists because established radiopharmaceutical providers face competition from therapeutic radionuclides with different emission types and external beam radiotherapy remains a common treatment approach. The company needs to maintain medical education programs and health-economic evidence and reliable radioisotope-based pain management logistics to protect its market share and increase treatment numbers in busy nuclear medicine departments. The company should focus on obtaining hospital system contracts and working with value-based oncology programs and building strategic relationships with pain and spine clinics that can direct suitable patients to Samarium-153 EDTMP instead of using systemic analgesics.
The Asia-Pacific region experiences three main factors which drive Samarium-153 EDTMP adoption because of its increasing cancer cases and rising healthcare spending and fast nuclear medicine facility development. The current market access for Samarium-153 EDTMP exists mainly through large urban Hospitals yet Specialty Clinics in major metropolitan areas present an untapped opportunity for structured bone metastases treatment services. The market requires specific access strategies which combine affordable pricing with medical value through multiple pricing tiers and radiopharmaceutical packaging deals and training programs for nuclear medicine and oncology staff to perform Samarium-153 EDTMP treatments safely. The market faces competition from affordable generic radioisotopes and first-line bone pain treatment through external beam radiotherapy and limited awareness about bone pain palliation agents which exist mainly in top cities. The market requires specific clinical education initiatives and demonstration studies to demonstrate Samarium-153 EDTMP effectiveness for treating metastatic prostate cancer and other skeletal metastases outside major cities. The strategic investment should establish reference centers in academic hospitals with leading status before expanding their expertise and patient referral networks to Specialty Clinics and Others (advanced diagnostic centers) for developing regional centers of excellence that will establish Samarium-153 EDTMP as a standard radiopharmaceutical therapy option in Asia-Pacific markets with high growth potential.

Market Dynamics and Supply Chain

01

Driver: Innovative Applications in Oncology, and Increasing Incidence of Cancer

Samarium-153 EDTMP offers a remedy for alleviating pain in individuals with cancer related bone metastases in a way that could also have also significant implications in the field of oncology due to its ability to target cancer cells while minimizing harm to nearby healthy tissues This increasing need for advanced oncology treatments is also likely to spur market expansion and create new opportunities, for utilizing Samarium-153 EDTMP.

With the increase in cancer cases worldwide comes a growing demand for treatments to address this pressing issue swiftly and effectively. Samarium-153 EDTMP capacity to alleviate pain in cancers—especially those linked to bone metastases—makes it a crucial asset in combatting this illness. Hence the rise in cancer cases plays a role, in propelling the growth of the Samarium-153 EDTMP market.

The rise of technological platforms in nuclear medicine has also broadened the utilization of therapeutic substances such as Samarium-153 EDTMP. The heightened awareness of its high energy beta particles within the medical field is also growing steadily due to their promising healing properties. With technological advancements the scope for further applications of Samarium-153 EDTMP is also expanding, solidifying technologys significance, in the market.

02

Restraint: Limited Awareness

Though Samarium-153 EDTMP shows promise for therapy purposes its reach is hindered by a lack of knowledge about it in developing countries. This lack of awareness among both professionals and patients restricts its adoption in the market. A limited understanding typically leads to demand, which can have a direct effect, on market trends and regulations.

03

Opportunity: Rising cancer burden in Asia-Pacific driving hospital adoption of Samarium-153 EDTMP bone pain palliation therapies and Expanding palliative demand among elderly metastatic prostate cancer patients driving Samarium-153 EDTMP uptake in oncology

The Asia-Pacific region is experiencing a transformation of its cancer centers and public healthcare systems through strategic radiopharmaceutical collaborations for Samarium-153 EDTMP. The Asia-Pacific region contains a substantial unexplored market for Samarium-153 EDTMP radiopharmaceutical injections because cancer cases continue to rise while palliative care remains underdeveloped. The radioisotope supply chain becomes secure through hospital-isotope producer-global pharma company partnerships which also enables affordable local production of the radiopharmaceutical. The region of China, India and Southeast Asia leads the world in adopting Targeted Radionuclide Therapy for bone pain palliation and oncology supportive care services through Samarium-153 EDTMP.

The increasing need for Samarium-153 EDTMP has transformed palliative care treatment for elderly patients with metastatic prostate cancer. The rising number of elderly patients with metastatic castration-resistant prostate cancer requires effective bone pain management, making Samarium-153 EDTMP an attractive option for advanced palliative care. The indication segment is projected to expand from 13.62 million in 2025 to 20.51 million by 2030 at an 8.53% CAGR, exceeding core indication growth rates. Highest demand exists for repeat-dose regimens and outpatient nuclear medicine services, as flexible dosing protocols help maximize patient quality-of-life benefits.

04

Challenge: High Cost of Treatment

The use of Samarium-153 EDTMP therapy can be expensive, limiting its accessibility to patients in many regions. The high treatment cost, combined with limited reimbursement options, can discourage healthcare providers from adopting it widely, ultimately restraining market growth and influencing overall adoption rates.

Supply Chain Landscape

1

Rare Earth Mining

Lynas CorporationChina Northern Rare Earth Group
2

Isotope Production

NTP Radioisotopes SOC Ltd.ANSTO
3

Samarium-153 EDTMP

Lantheus Medical Imaging Inc.Curium Pharma
4

Bone Metastases Treatment

Oncology hospitalsNuclear medicine centersRadiotherapy clinics
Samarium-153 EDTMP - Supply Chain

Use Cases of Samarium-153 EDTMP in Bone Pain Palliation & Radiotherapy

Bone Pain Palliation : In practice mainly and commonly used in treating bone pain caused by osteoblastic metastatic bone tumors is Samarium-153 EDTMP compound medication. It offers relief for patients with widespread skeletal metastases by specifically addressing region's of discomfort. The key players in this field consist of known pharmaceutical firms leveraging Samarium-153 EDTMP benefits, in managing bone pain successfully.
Osteosarcoma Treatment : Samarium-153 EDTMP is frequently used in treating osteosarcoma as it emits both beta particles and diagnostic gamma rays making it an effective option for managing both localized and metastatic forms of the disease. Specialized companies in medicine and radiopharmaceuticals lead the market in utilizing this treatment for osteosarcoma patients due to its significant advantages, in therapy.
Radiotherapy : Samarium-153 EDTMP is widely used in radiotherapy to deliver a radiation dose to cancer cells without harming nearby healthy tissue—a key strategy that companies, in the radiotherapy sector are leveraging to improve treatment effectiveness and strengthen their market presence.

Recent Developments

Recent developments in Samarium-153 EDTMP focus on enhancing radiopharmaceutical efficacy and expanding its use in bone-targeted therapies for metastatic cancer patients. Innovations in beta-emitting radiotherapy and flexible dosing protocols have improved patient outcomes and facilitated outpatient nuclear medicine applications. A key market trend is the increasing demand for palliative care among elderly patients with metastatic prostate and breast cancers, driving broader adoption. These advances position Samarium-153 EDTMP as a pivotal solution in precision oncology and supportive care strategies.

December 2024 : Johnson & Johnson has made an investment, in the Samarium-153 EDTMP market as part of its strategy to enhance its radiopharmaceutical portfolio.
November 2024 : Mitsubishi Chemical Holdings is a player in the chemical sector and has launched an innovative research program to explore the potential medical uses of Samarium-153 EDTMP, in treating variouss of cancer.
September 2024 : Novartis acquired a startup that focuses on developing Samarium-153 EDTMP as part of its move towards providing solutions, for cancer treatment using radiopharmaceuticals.

Impact of Industry Transitions on the Samarium-153 EDTMP Market

As a core segment of the Pharmaceutical industry, the Samarium-153 EDTMP market develops in line with broader industry shifts. Over recent years, transitions such as From Niche Palliative to Strategic Radiopharmaceutical Asset and Advancements in Radiopharmaceuticals have redefined priorities across the Pharmaceutical sector, influencing how the Samarium-153 EDTMP market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

From Niche Palliative to Strategic Radiopharmaceutical Asset

The Samarium-153 EDTMP market has evolved from its initial position as a specialized bone metastasis treatment for palliative care into a fundamental element of the expanding radiopharmaceuticals industry. The growing adoption of targeted radionuclide therapies in oncology practices has led healthcare organizations to assess Samarium-153 EDTMP's position in outpatient cancer treatment protocols which will optimize resource utilization and reduce hospital admissions. The industry will achieve $7 million in additional revenue through 2030 because hospitals understand Samarium-153 EDTMP provides better value than expensive imaging methods and surgical interventions. The increasing need for systemic bone pain palliation will drive radioisotope suppliers to enhance their production reliability and regulatory compliance which will establish Samarium-153 EDTMP as a leading treatment for advanced cancer care. This industry transition is expected to add $8 million in the industry revenue between 2025 and 2030.
02

Advancements in Radiopharmaceuticals

The healthcare sector has witnessed substantial progress in the development of radiopharmaceutical agents, exemplified by the use of Samarium-153 EDTMP. As a beta-emitting radiopharmaceutical, it specifically targets osteoblastic bone abnormalities, allowing for precise therapeutic applications in bone-related conditions such as metastatic bone pain associated with prostate or breast cancer. Advances in radiochemistry, formulation, and delivery techniques have enhanced its efficacy, safety, and patient tolerability. These innovations enable clinicians to provide targeted treatment with minimal systemic exposure, improving patient outcomes and quality of life, and reinforcing the role of Samarium-153 EDTMP in modern palliative oncology care.